133 related articles for article (PubMed ID: 22265973)
21. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.
Dong M; Richards DA; Goodnough MC; Tepp WH; Johnson EA; Chapman ER
J Cell Biol; 2003 Sep; 162(7):1293-303. PubMed ID: 14504267
[TBL] [Abstract][Full Text] [Related]
22. Structure of dual receptor binding to botulinum neurotoxin B.
Berntsson RP; Peng L; Dong M; Stenmark P
Nat Commun; 2013; 4():2058. PubMed ID: 23807078
[TBL] [Abstract][Full Text] [Related]
23. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other.
Atassi MZ; Taruishi M; Naqvi M; Steward LE; Aoki KR
Protein J; 2014 Jun; 33(3):278-88. PubMed ID: 24740609
[TBL] [Abstract][Full Text] [Related]
24. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay.
Li L; Singh BR
J Nat Toxins; 1998 Oct; 7(3):215-26. PubMed ID: 9783260
[TBL] [Abstract][Full Text] [Related]
25. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner.
Strotmeier J; Lee K; Völker AK; Mahrhold S; Zong Y; Zeiser J; Zhou J; Pich A; Bigalke H; Binz T; Rummel A; Jin R
Biochem J; 2010 Oct; 431(2):207-16. PubMed ID: 20704566
[TBL] [Abstract][Full Text] [Related]
26. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
27. Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B.
Sikorra S; Henke T; Swaminathan S; Galli T; Binz T
J Mol Biol; 2006 Mar; 357(2):574-82. PubMed ID: 16430921
[TBL] [Abstract][Full Text] [Related]
28. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
29. Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins.
Thaker H; Zhang J; Miyashita SI; Cristofaro V; Park S; Hashemi Gheinani A; Sullivan MP; Adam RM; Dong M
PLoS Pathog; 2021 Oct; 17(10):e1009994. PubMed ID: 34662366
[TBL] [Abstract][Full Text] [Related]
30. Synaptotagmin Binding to Botulinum Neurotoxins.
Martínez-Carranza M; Blasco P; Gustafsson R; Dong M; Berntsson RP; Widmalm G; Stenmark P
Biochemistry; 2020 Feb; 59(4):491-498. PubMed ID: 31809018
[TBL] [Abstract][Full Text] [Related]
31. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
Schmidt JJ; Stafford RG
Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
[TBL] [Abstract][Full Text] [Related]
32. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
Masuyer G; Beard M; Cadd VA; Chaddock JA; Acharya KR
J Struct Biol; 2011 Apr; 174(1):52-7. PubMed ID: 21078393
[TBL] [Abstract][Full Text] [Related]
33. Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains.
Ebrahimi F; Rasaee MJ; Mousavi SL; Babaeipour V
J Toxicol Sci; 2010 Feb; 35(1):9-19. PubMed ID: 20118620
[TBL] [Abstract][Full Text] [Related]
34. Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors.
Tao L; Peng L; Berntsson RP; Liu SM; Park S; Yu F; Boone C; Palan S; Beard M; Chabrier PE; Stenmark P; Krupp J; Dong M
Nat Commun; 2017 Jul; 8(1):53. PubMed ID: 28674381
[TBL] [Abstract][Full Text] [Related]
35. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a.
Nishiki T; Tokuyama Y; Kamata Y; Nemoto Y; Yoshida A; Sato K; Sekiguchi M; Takahashi M; Kozaki S
FEBS Lett; 1996 Jan; 378(3):253-7. PubMed ID: 8557112
[TBL] [Abstract][Full Text] [Related]
36. A new neutralizing antibody against botulinum neurotoxin B recognizes the protein receptor binding sites for synaptotagmins II.
Wang H; Li T; Shi J; Cai K; Hou X; Wang Q; Xiao L; Tu W; Liu H; Gao X
Microbes Infect; 2010 Nov; 12(12-13):1012-8. PubMed ID: 20650331
[TBL] [Abstract][Full Text] [Related]
37. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
38. Molecular landscape of BoNT/B bound to a membrane-inserted synaptotagmin/ganglioside complex.
Ramirez-Franco J; Azzaz F; Sangiardi M; Ferracci G; Youssouf F; Popoff MR; Seagar M; Lévêque C; Fantini J; El Far O
Cell Mol Life Sci; 2022 Aug; 79(9):496. PubMed ID: 36006520
[TBL] [Abstract][Full Text] [Related]
39. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin.
Edupuganti OP; Ovsepian SV; Wang J; Zurawski TH; Schmidt JJ; Smith L; Lawrence GW; Dolly JO
FEBS J; 2012 Jul; 279(14):2555-67. PubMed ID: 22607388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
